Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study.


Journal

Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353

Informations de publication

Date de publication:
04 2021
Historique:
received: 12 10 2020
revised: 13 11 2020
accepted: 16 11 2020
pubmed: 5 12 2020
medline: 6 7 2021
entrez: 4 12 2020
Statut: ppublish

Résumé

This study assessed symptoms and their determinants 1.5-6 months after symptom onset in non-hospitalised subjects with confirmed COVID-19 until 1 June 2020, in a geographically defined area. We invited 938 subjects; 451 (48%) responded. They reported less symptoms after 1.5-6 months than during COVID-19; median (IQR) 0 (0-2) versus 8 (6-11), respectively (p<0.001); 53% of women and 67% of men were symptom free, while 16% reported dyspnoea, 12% loss/disturbance of smell, and 10% loss/disturbance of taste. In multivariable analysis, having persistent symptoms was associated with the number of comorbidities and number of symptoms during the acute COVID-19 phase.

Identifiants

pubmed: 33273028
pii: thoraxjnl-2020-216377
doi: 10.1136/thoraxjnl-2020-216377
pmc: PMC7716295
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

405-407

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. WG reports grants and personal fees from Novartis, grants and personal fees from Amgen, grants from Bayer, grants from BMS, grants from Pfizer, personal fees from MSD, outside the submitted work. The other authors declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Auteurs

Knut Stavem (K)

Department of Pulmonary Medicine, Akershus University Hospital, Lørenskog, Norway knut.stavem@medisin.uio.no.
Health Services Research Unit, Akershus University Hospital, Lørenskog, Norway.
Institute of Clinical Medicine, Campus Ahus, Faculty of Medicine, University of Oslo, Lørenskog, Norway.

Waleed Ghanima (W)

Haematology and Oncology, Sykehuset Østfold HF, Grålum, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Magnus Kringstad Olsen (MK)

Department of Research, Sykehuset Østfold HF, Grålum, Norway.

Hanne Margrethe Gilboe (HM)

Medical Microbiology, Fürst Medisinsk Laboratorium, Oslo, Norway.

Gunnar Einvik (G)

Department of Pulmonary Medicine, Akershus University Hospital, Lørenskog, Norway.
Institute of Clinical Medicine, Campus Ahus, Faculty of Medicine, University of Oslo, Lørenskog, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH